Skip to main content
OpenTrials
Completed

NCT Number: NCT03547050

Rolandic Epilepsy Genomewide Association International Study

We have discovered a small change in the genetic code which increases the risk of the brainwave abnormality that is found in rolandic epilepsy. We now wish to confirm this using a second much larger sample of patients. We will investigate the other genetic changes that cause people with the brainwave abnormality to develop seizures, as well as problems with speech, coordination, attention and learning.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rolandic Epilepsy Brain Diseases Central Nervous System Diseases Epilepsies, Partial Epilepsy Epilepsy, Rolandic Epileptic Syndromes Nervous System Diseases

Age range

6 year–25 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Dr. Juan P. Garrahan Children's Hospital, Buenos Aires, Argentina

Loading trial locations.

About this study

Epilepsy is a common neurological disorder affecting 1% of the population. There are over 30 types of epilepsy, some common, some rare. Most epilepsies arise in childhood and have a genetic cause. Approximately 25% of child patients have "Rolandic Epilepsy" or RE, also known as Benign Epilepsy with Centrotemporal Spikes (BECTS). RE has a complex genetic basis, probably made up of combinations of susceptibility variants in different genes. Children with RE quite often have other symptoms that affect their speech, attention, reading ability or coordination. The goal of this study is to find the genetic basis for susceptibility to seizures and associated comorbidities for RE using genomewide association approaches.

We know that RE has a genetic basis and we recently discovered the genetic cause of the EEG pattern seen in RE. The goal of REGAIN is to now find the genetic basis for susceptibility to seizures and the associated symptoms above. Our hope is to be able to improve diagnosis and understand why each child with RE is different, and perhaps point us towards new treatments that are more effective and have fewer side effects.

We will compare the genetic code of 3,000 children with RE against a similar number of people not affected by epilepsy. With the proposed large sample of participants, we will be able to pinpoint the exact changes that might lead to seizures or attention problems for example. Learning the genetic basis for these problems will deepen our understanding of the mechanisms and lead to new treatments or cures.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of Rolandic Epilepsy in accordance with the following international criteria:
  • Age of first afebrile seizure 3-12 years
  • Seizures comprising focal sensorimotor seizures affecting the vocal tract and face, with or without involvement of the arm
  • Predominant sleep-related seizures
  • EEG interictal centro-temporal spikes with normal background
  • Current age 6-25 years

Exclusion criteria

  • No history of focal seizure
  • Normal EEG or abnormal background features on EEG
  • Known structural causes (stroke, tuberous sclerosis, infection, post-infectious or metabolic)
  • Primary diagnosis of autism or global learning disability
  • Focal central neurological deficit on clinical exam,
  • Unable to provide informed consent
  • Unable to provide blood sample

Treatment and study plan

Blood Draw

Other

Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.

Existing samples

Other

Control DNA samples will be used that have been previously acquired in other studies.

Primary outcomes

  1. Allelic association p value corrected for genome wide testing

    Time frame: Day 1

    We will look to see if there are changes in the genetic code that cause brainwave abnormalities close to the genetic changes that we have already discovered.

Sponsors and collaborators

Lead sponsor

King's College London

Other

Collaborators

  • Aghia Sophia Children's Hospital of Athens
  • Cardiff University
  • Columbia University
  • Guy's and St Thomas' NHS Foundation Trust
  • Hasbro Children's Hospital
  • Hospital JP Garrahan
  • Hospital Mutua de Terrassa
  • King's College Hospital NHS Trust
  • Seattle Children's Hospital
  • The Hospital for Sick Children

Registry information

Acronym: REGAIN

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Jun 6, 2018
Registry last updated
Oct 6, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.